REG - Cambridge Cognition - Contract Win

Cambridge Cognition HoldingsAnnouncement

03/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250403:nRSC4353Da&default-theme=true

RNS Number : 4353D  Cambridge Cognition Holdings PLC  03 April 2025

 

3rd April 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Contract Win

Cambridge Cognition selected for two Phase 3 trials combining digital
cognitive and voice solutions

Cambridge Cognition (AIM: COG), the brain health software group specialising
in digital products to advance clinical research and patient treatment, has
been selected by a major pharmaceutical company to provide digital cognitive
and voice assessments for two Phase 3 clinical trials in adolescents with
Major Depressive Disorder (MDD). Both contracts are set to commence this year,
with the first running until 2027 and the second through to 2029. The total
value of the combined contracts is estimated at approximately £1.2 million.

MDD among adolescents represents a critical public health challenge with
significant long-term implications(1). The past three years have witnessed a
substantial 30% growth in industry-sponsored clinical studies focused on
depression(2), highlighting an increasing research commitment to mental health
interventions. The market for MDD is expected to exceed $19 billion by
2030(3).

Cambridge Cognition has been selected as a strategic partner to advance
clinical trial methodologies through innovative speech analysis. By
integrating speech biomarkers with cognitive assessments, the platform enables
more precise patient monitoring, allowing researchers to capture nuanced
treatment-response insights. Additionally, the inclusion of cognitive
assessments will enable detection of improvements in cognitive function, which
is frequently impaired in depression and closely linked to overall
functioning.

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

"This strategically important contract win highlights the value of our
integrated speech and cognitive platform that not only delivers robust and
reliable results for the pharmaceutical company but also reduces trial costs
and patient burden. As a result, we see significant future demand for our
unique platform, and we remain confident in our ambitions to significantly
grow sales in the high-impact, late-stage CNS trials market over the coming
years."

1.     Thapar, A., Collishaw, S., Pine, D. S., & Thapar, A. K. (2012).
Depression in adolescence. The Lancet, 379(9820), 1056-1067.

2.     Data sourced from Citeline's Trial Trove, Informa Pharma
Intelligence, accessed March 2025

3.     Anxiety Disorders And Depression Treatment Market Size, Share &
Trends Analysis Report By Drug Type, By Indication (Depression, Anxiety), By
Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030. Grand
View Research

 

 

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Joint Managing Director and Chief Operating Officer   press@camcog.com (mailto:press@camcog.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Freddy Crossley / Will Goode / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Harry Griffiths                 cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital
health products that advance brain health research and treatment.

The company offers four core products: CANTAB® assessments-providing
scientifically validated, highly sensitive, precise, and objective measures of
cognitive function correlated to neural networks; a flexible and proven eCOA
platform with an extensive library of instruments, enabling efficient study
setup and scalable data capture; rater training services that standardise
assessment delivery and scoring across clinical trials and quality assurance
tools that ensure data integrity by automatically detecting deviations in
administration and scoring, saving time and money. These products collectively
improve clinical trial outcomes, enable early patient identification, and
enhance global efficiency in healthcare and pharmaceuticals.

 

For further information, visit: www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUUSKRVRUSRAR